E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

被引：0
|
作者：
Hilary Glen
Susan Mason
Hitesh Patel
Kenneth Macleod
Valerie G Brunton
机构：
[1] Beatson Institute for Cancer Research,Edinburgh Cancer Research Centre
[2] University of Edinburgh,undefined
来源：
BMC Cancer | / 11卷
关键词：
Fibroblast Growth Factor Receptor; Wound Healing Assay; Platelet Derive Growth Factor Receptor; U2OS Cell; Lymphatic Vessel Density;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
    Glen, Hilary
    Mason, Susan
    Patel, Hitesh
    Macleod, Kenneth
    Brunton, Valerie G.
    [J]. BMC CANCER, 2011, 11
  • [2] E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
    Wiegering, Armin
    Korb, Doreen
    Thalheimer, Andreas
    Kaemmerer, Ulrike
    Allmanritter, Jan
    Matthes, Niels
    Linnebacher, Michael
    Schlegel, Nicolas
    Klein, Ingo
    Erguen, Sueleyman
    Germer, Christoph-Thomas
    Otto, Christoph
    [J]. NEOPLASIA, 2014, 16 (11): : 972 - 981
  • [3] PHASE I/II TRIAL OF LENVATINIB (E7080), A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Ikeda, K.
    Kumada, H.
    Kudo, M.
    Kawazoe, S.
    Osaki, Y.
    Ikeda, M.
    Okusaka, T.
    Suzuki, T.
    O'Brien, J. P.
    Okita, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 244 - 244
  • [4] A PHASE II TRIAL OF THE MULTI-TARGETED KINASE INHIBITOR LENVATINIB (E7080) IN ADVANCED MEDULLARY THYROID CANCER (MTC)
    Schlumberger, M.
    Jarzab, B.
    Cabanillas, M. E.
    Robinson, B.
    Furio, P.
    Ball, D. W.
    McCaffrey, J. C.
    Newbold, K.
    Allison, R.
    Martins, R. G.
    Licitra, L.
    Shah, M. H.
    Bodenner, D. L.
    Elisei, R.
    Burmeister, L. A.
    Funahashi, Y.
    Sellecchia, R.
    Andresen, C.
    O'Brien, J. P.
    Sherman, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 35 - 36
  • [5] A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Molina, Ana M.
    Hutson, Thomas E.
    Larkin, James
    Gold, Anne M.
    Wood, Karen
    Carter, Dave
    Motzer, Robert
    Michaelson, M. Dror
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 181 - 189
  • [6] A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Ana M. Molina
    Thomas E. Hutson
    James Larkin
    Anne M. Gold
    Karen Wood
    Dave Carter
    Robert Motzer
    M. Dror Michaelson
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 73 : 181 - 189
  • [7] Correlation of Serum Biomarkers and Clinical Outcomes to Identify Predictors of Response to the Multi-targeted Kinase Inhibitor E7080 in Patients With Advanced Melanoma
    Hong, D.
    Nemunaitis, J.
    Funahashi, Y.
    O'Brien, J. P.
    Verbel, D.
    Kadowaki, T.
    Simon, J.
    Eisen, A.
    Lucy, X.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S123 - S123
  • [8] PHASE I STUDY OF E7080, A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN COMBINATION WITH CARBOPLATIN PLUS PACLITAXEL IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Nishio, Makoto
    Horiike, Atsushi
    Horai, Takeshi
    Takahashi, Toshiaki
    Murakami, Haruyasu
    Yamamoto, Nobuyuki
    Yusa, Wataru
    Tamura, Tomohide
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1207 - S1208
  • [9] Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
    Okamoto, Kiyoshi
    Kodama, Kotaro
    Takase, Kazuma
    Sugi, Naoko Hata
    Yamamoto, Yuji
    Iwata, Masao
    Tsuruoka, Akihiko
    [J]. CANCER LETTERS, 2013, 340 (01) : 97 - 103
  • [10] E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
    Ikuta, Kenji
    Yano, Seiji
    Trung, Van The
    Hanibuchi, Masaki
    Goto, Hisatsugu
    Li, Qi
    Wang, Wei
    Yamada, Tadaaki
    Ogino, Hirokazu
    Kakiuchi, Soji
    Uehara, Hisanori
    Sekido, Yoshitaka
    Uenaka, Toshimitsu
    Nishioka, Yasuhiko
    Sone, Saburo
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7229 - 7237
12345